Curanex Pharmaceuticals Inc Common Stock (CURX) Stock Score, Valuation & Financial Research

Curanex Pharmaceuticals Inc Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CURX

Curanex Pharmaceuticals Inc Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 5.03. These figures are a research snapshot, not a buy or sell recommendation.

What Curanex Pharmaceuticals Inc Common Stock does

Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Curanex Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative botanical drugs. The company currently operates as a research and development entity, generating no commercial revenue as it advances its pipeline through preclinical studies and prepares for IND submissions.

Products and services

  • The company's primary product candidate is Phyto-N, a botanical drug candidate currently being developed for the treatment of ulcerative colitis and other inflammatory diseases.

Brands and product families

  • Phyto-N — Lead botanical drug candidate for the treatment of ulcerative colitis. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the scale-up and production of GMP-compliant pilot material for its drug candidates. Source

Business strengths to evaluate

  • Advancement of Phyto-N pipeline and CMC execution Source

Business risks and research considerations

  • Clinical development and regulatory approval risks Source
  • Dependence on third-party manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CURX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.03
Market capitalization:
7.13M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.47M
Free cash flow:
USD -10.48M
Cash:
USD 2.94M
Total debt:
USD 276.36K
EPS:
USD -7.38

What stands out

  • Free cash flow is USD -10.48M, negative for the stored period.
  • The balance sheet shows USD 2.94M of cash versus USD 276.36K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CURX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CURX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CURX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CURX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of CURX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CURX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.